Table 2.
Analysis of viral load for HPV types 5, 8, 15, 23 and 24 in each sample group.
| Sample Group1 |
Q-PCR positive | |||||
|---|---|---|---|---|---|---|
| Total | HPV52 | HPV8 | HPV15 | HPV23 | HPV24 | |
| OTR SCC (n=13) |
38% (5) | 75% (3 of 4); 1 per 97,1 per 883, 1 per 4702 |
50% (1 of 2); 1 per 4445 |
14% (1 of 7); 1 per 176 |
11% (1 of 9); 1 per 30 |
33% (1 of 3); 1 per 1407 |
| IC SCC (n=7) |
29% (2) | 50% (1 of 2); 1 per 320 |
50% (1 of 2); 1 per 80 |
0 (0) | 0(1) | 0(2) |
| RDEB SCC (n=12) |
25% (3) | 50% (1 of 2); 1 per 674 |
66% (2 of 3); 1 per 15, 1 per 393 |
0(4) | 17% (1 of 6); 1 per 9 |
33% (1 of 3); 1 per 79 |
| RDEB peri- lesional skin; patients with SCC (n=3) |
67% (2) | 0(0) | 100% (2 of 2); 1 per 38, 1 per 58 |
0(0) | 0(2) | 0(2) |
| RDEB normal skin; patients without SCC (n=8) |
0% | 0(0) | 0(0) | 0(0) | 0(8) | 0(0) |
Abbreviations: HPV, human papillomavirus; IC, immunocompetent; OTR, organ transplant recipient; Q-PCR, quantitative PCR; RDEB, recessive dystrophic epidermolysis bullosa; RHA, reverse hybridization assay; SCC, squamous cell carcinoma.
1
Number of samples positive for types 5, 8, 15, 23 or 24 by RHA: note that figures are not additive due to the presence of multiple infections.
2
Viral loads were calculated per cell equivalent by normalizing to beta globin.